Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort

Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort

Description

Background: The etiology of prostate cancer (PCa) involves environmental and genetic factors. Understanding the role of medication use on PCa risk may clarify the pathophysiological changes and mechanisms in development of cancer. Methods: This study investigated PCa risk in relation to overall use of anti-hypertensive drugs and those with specific mechanisms of action. The study cohort (78,615 men) was linked to the prescription database to obtain information on medication use during 20-year follow-up. Information was obtained on PCa diagnoses, causes of deaths, and for a sub-set on B.M.I. and use of non-prescription drugs. Time-dependent drug use variables hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox regression analyses. Results: Use of antihypertensive drugs slightly increased PCa risk (HR = 1.16, 95% CI = 1.11–1.22). The risk increase was clearest for metastatic PCa (HR = 1.36, 95% CI = 1.14–1.62). ACE inhibitors, beta-blockers, and diuretics were all separately associated with a small excess risk (HR = 1.10, 95% CI = 1.01–1.19, HR = 1.14, 95% CI = 1.06–1.21, and HR = 1.16, 95% CI = 1.07–1.27, respectively). None of the other groups showed a clear association with PCa risk. Conclusions: The use of antihypertensive drugs was associated with increased prostate cancer risk. Similar risk association for multiple drug groups suggests that the findings may not reflect a direct medication effect, but may be due to underlying hypertension.
Show more

Year of publication

2019

Authors

Aino Siltari - Creator

Anssi Auvinen - Creator

Teemu J. Murtola - Creator

Teuvo Tammela - Creator

Unknown organization

Kimmo Taari - Creator

Kirsi Talala - Creator

figshare - Publisher

Other information

Fields of science

Cancers; Surgery, anesthesiology, intensive care, radiology

Language

English

Open access

Open

License

Creative Commons Attribution 4.0 International (CC BY 4.0)

Keywords

genetics, Science Policy, Biotechnology, Medicine, Pharmacology, FOS: Biological sciences, cancer, 110309 Infectious Diseases, FOS: Health sciences